Proprietary Cell-sheet PlatformCellSeed’s specialized cell sheet engineering platform defines a clear, defensible niche in regenerative medicine. Proprietary manufacturing know-how and product/service integration support long-term differentiation versus generic biotechs, enabling durable clinical partnerships and licensing opportunities.

Strong Gross MarginsSustained gross margins near mid-to-high single digits above many peers indicate attractive unit economics for cell-based products. If fixed costs are rationalized, these margins provide a structural foundation to scale profitable product lines once revenue growth resumes.

Low Financial LeverageConservative debt levels give the company financial flexibility to fund R&D or toll manufacturing through equity or modest borrowing without excessive solvency risk. Low leverage reduces bankruptcy probability and supports strategic investments in clinical/commercial programs.

Bears Say

Severe Revenue DeclineA more than half drop in revenue signals structural demand or commercialization setbacks. Persistent top-line weakness undermines ability to absorb fixed costs, delays scale economies, and raises execution risk for moving from R&D to recurring commercial revenues.

Persistent Cash BurnConsistent negative operating and free cash flow indicate operations cannot self-fund. Ongoing cash burn forces dependence on external financing, increasing dilution or constrained investment in trials and commercialization, which materially raises long-term execution risk.

Large Operating Losses And Equity ErosionExtreme negative margins and declining shareholder equity reflect an unsustainable cost base relative to current revenues. Continued losses erode capital, restrict strategic options, and heighten the likelihood of restructuring, asset sales, or substantial new capital raises that dilute existing shareholders.

CellSeed Inc. News

CellSeed Inc.’s Promising Phase III Study on Knee Osteoarthritis Treatment

CellSeed Inc. (($JP:7776)) announced an update on their ongoing clinical study. Study Overview: CellSeed Inc. is conducting a...

4M ago

7776

7776 FAQ

What was CellSeed Inc.’s price range in the past 12 months?

CellSeed Inc. lowest stock price was ¥231.00 and its highest was ¥742.00 in the past 12 months.

What is CellSeed Inc.’s market cap?

CellSeed Inc.’s market cap is ¥13.62B.

When is CellSeed Inc.’s upcoming earnings report date?

CellSeed Inc.’s upcoming earnings report date is May 18, 2026 which is in 72 days.

How were CellSeed Inc.’s earnings last quarter?

CellSeed Inc. released its earnings results on Feb 13, 2026. The company reported -¥7.31 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.31.

Is CellSeed Inc. overvalued?

According to Wall Street analysts CellSeed Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CellSeed Inc. pay dividends?

CellSeed Inc. does not currently pay dividends.

What is CellSeed Inc.’s EPS estimate?

CellSeed Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CellSeed Inc. have?

CellSeed Inc. has 38,474,320 shares outstanding.

What happened to CellSeed Inc.’s price movement after its last earnings report?

CellSeed Inc. reported an EPS of -¥7.31 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.305%.

Which hedge fund is a major shareholder of CellSeed Inc.?

Currently, no hedge funds are holding shares in JP:7776

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

CellSeed Inc.

CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides peripheral equipment, including ThermoPlate III, a heating element made by a transparent glass plate; and cellZscope, an automated cell monitoring system, as well as contract development and manufacturing services. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.